Search results
Search for "CD163" in Full Text gives 2 result(s) in Beilstein Journal of Nanotechnology.
Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy
Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10
- delivery vehicles. Antibody-functionalized NCs are a powerful method for selective drug delivery. For example, anti-CD163 antibodies can be conjugated to NCs to target M2 macrophages specifically. This strategy has shown significant promise in modulating TAMs by delivering agents that either reprogram or
- inflammation and tissue damage in RA models [75]. Beyond cytokines, mRNA therapies have targeted macrophage-specific markers to induce phenotype switching. Polyethylenimine NPs grafted with mannose ligands have been used to deliver genes encoding CD163, a hallmark of M2 macrophages. This system successfully
Recognition mechanisms of hemoglobin particles by monocytes – CD163 may just be one
Beilstein J. Nanotechnol. 2023, 14, 1028–1040, doi:10.3762/bjnano.14.85
- common that they are affected by degradation and excretion at an early stage in test organisms. Several possible mechanisms that may be responsible for this are discussed in the literature. One of them is CD163, the receptor of the complex of haptoglobin (Hp) and hemoglobin (Hb). The receptor has been
- shown in various studies to have a direct affinity for Hb in the absence of Hp. Thus, it seems reasonable that CD163 could possibly also bind Hb within HBOCs and cause phagocytosis of the particles. In this work we investigated the role of CD163 in the uptake of our hemoglobin sub-micron particles
- (HbMPs) in monocytes and additionally screened for alternative ways of particle recognition by monocytes. In our experiments, blockade of CD163 by specific monoclonal antibodies proved to partly inhibit HbMP uptake by monocytes. It appears, however, that several other phagocytosis pathways for HbMPs
Other Beilstein-Institut Open Science Activities
